Daily Respiratory Research Analysis
Analyzed 69 papers and selected 3 impactful papers.
Summary
Analyzed 69 papers and selected 3 impactful articles.
Selected Articles
1. Non-invasive respiratory supports and criteria for intubation in randomised trials of acute hypoxaemic respiratory failure: a systematic review and network meta-analysis.
Across 44 RCTs enrolling 9,704 adults with AHRF, CPAP, HFNC, and bilevel NIPPV probably reduce intubation compared with standard oxygen therapy, with CPAP and HFNC possibly lowering mortality. Prespecified criteria for intubation were common but did not modify treatment effects, supporting generalizability to settings without explicit intubation rules.
Impact: This up-to-date network meta-analysis directly informs frontline AHRF management by clarifying comparative effects of non-invasive supports on intubation and mortality and addresses a key methodological concern regarding intubation criteria.
Clinical Implications: Prioritize CPAP or HFNC for eligible AHRF patients to reduce intubation risk; bilevel NIPPV remains reasonable but may not reduce mortality. Institutions can adopt these strategies without needing rigid intubation criteria for comparability to trial settings.
Key Findings
- CPAP (OR 0.45, 95% CrI 0.27–0.72), HFNC (OR 0.61, 0.42–0.86), and bilevel NIPPV (OR 0.60, 0.39–0.89) probably reduce intubation versus standard oxygen therapy.
- CPAP (OR 0.73, 0.55–0.95) and HFNC (OR 0.83, 0.66–0.98) may reduce mortality; bilevel NIPPV may not (OR 0.93, 0.71–1.17).
- Use of explicit intubation criteria across trials (84%) did not modify treatment effects in network meta-regression.
Methodological Strengths
- Pre-registered protocol and comprehensive multi-database search with PRISMA-concordant methodology.
- Network meta-analysis with GRADE certainty assessment and RoB 2 risk-of-bias evaluation; meta-regression probing intubation criteria.
Limitations
- Mortality effects are of low certainty and may be influenced by trial heterogeneity and co-interventions.
- Population exclusions (e.g., predominant COPD or CHF, post-extubation) limit generalizability to those subgroups.
Future Directions: Head-to-head RCTs of CPAP vs HFNC with standardized weaning/intubation protocols and patient-centered outcomes; implementation studies in diverse resource settings.
BACKGROUND: Patients with acute hypoxaemic respiratory failure (AHRF) can be treated with non-invasive respiratory supports. We aimed to update a network meta-analysis of these treatments, and investigate whether the use of criteria for intubation in trials influences treatment effects on intubation or mortality. METHODS: For this systematic review and meta-analysis, we updated a literature search that was done in 2022 for the previous network meta-analysis examining non-invasive oxygen supports for AHRF. We searched MEDLINE, Embase, Cochrane CENTRAL, CINAHL, Web of Science, and PubMed databases from database inception to Nov 18, 2025, for randomised controlled trials studying adults (18 years or older) with AHRF, comparing non-invasive respiratory supports or comparing the use of non-invasive respiratory support to standard oxygen therapy (SOT). We excluded trials enrolling patients already receiving invasive ventilation, trials that included invasive ventilation as an intervention, trials where the majority (>50%) of patients had congestive heart failure or chronic obstructive pulmonary disease as their primary reason for respiratory failure, and trials focusing on patients who were immediately postextubation or postoperative. Data were extracted from published reports. We catalogued intubation criteria and performed a network meta-analysis comparing the effects of continuous positive airway pressure (CPAP), high-flow nasal cannula (HFNC), and bilevel non-invasive positive pressure ventilation (NIPPV) on intubation and mortality, presented as odds ratios (ORs) and 95% credible intervals (CrIs) relative to SOT. We assessed risk of bias with the RoB 2 tool and certainty with the GRADE approach. We used network meta-regression to assess whether trials with intubation criteria found different treatment effects. The protocol was pre-registered on Jan 23, 2024, with Open Science Framework, https://osf.io/f8qeh. FINDINGS: We included 44 trials (33 from previous review, 11 newly identified) that enrolled 9704 patients. The median proportion of participants who were female was 37% (IQR 29-45) and the median proportion male was 63% (55-71). The network for intubation included 8790 patients and 42 comparisons from 37 trials. The network for mortality included 8789 patients and 39 comparisons from 34 trials. Intubation criteria were present in 37 (84%) trials, and most pertained to oxygenation, ventilation, or neurological state. Compared with SOT, CPAP (OR 0·45, 95% CrI 0·27-0·72), HFNC (OR 0·61, 0·42-0·86), and bilevel NIPPV (OR 0·60, 0·39-0·89) probably reduce intubation (all moderate certainty). CPAP (OR 0·73, 0·55-0·95) and HFNC (OR 0·83, 0·66-0·98) may reduce mortality compared with SOT (both low certainty), whereas bilevel NIPPV (OR 0·93, 0·71-1·17; low certainty) may not. Criteria for intubation were not associated with differences in treatment effects. INTERPRETATION: Compared with SOT, CPAP, HFNC, and bilevel NIPPV probably reduce intubation, and CPAP and HFNC may reduce mortality. Criteria for intubation were common but were not associated with differences in treatment efficacy. These findings can guide the selection of non-invasive respiratory supports for patients, inform policymakers regarding the utility of non-invasive respiratory supports, and provide reassurance that results from trials incorporating intubation criteria likely extend to contexts where explicit intubation criteria are not used. FUNDING: JP Bickell Foundation.
2. RAISE: A computational tool for evaluating sarbecovirus spillover potential.
RAISE integrates structural modeling and interaction scoring to categorize sarbecoviruses by hACE2-binding potential, identifying specific mutations (e.g., T498Y/W) that enable ACE2 use. The framework generalizes to merbecoviruses, providing a prioritization roadmap for surveillance and pandemic preparedness.
Impact: This work delivers a mechanistically grounded, prospectively useful framework to preemptively flag zoonotic risks and actionable mutations across coronavirus lineages.
Clinical Implications: Supports risk-based surveillance and vaccine/therapeutic antigen design by predicting emergent ACE2-binding variants before widespread human transmission.
Key Findings
- RAISE stratifies sarbecoviruses into high, negligible, and poised hACE2-binding categories via structure-based interaction scoring.
- Mutation scans identified T498Y/W enabling human ACE2 usage in poised viruses (e.g., Khosta-1, PDF-2370) and broadened cross-species ACE2 binding.
- Prospective application to merbecoviruses demonstrated generalizability for cross-lineage zoonotic risk assessment.
Methodological Strengths
- Integration of structural prediction with quantitative receptor-binding interaction scoring.
- Experimental mutation screening validating model predictions and demonstrating cross-lineage generalizability.
Limitations
- Computational predictions and in vitro validations may not fully capture in vivo fitness, transmissibility, or pathogenicity.
- Potential model bias due to training data and structural prediction uncertainties.
Future Directions: Couple RAISE outputs with phenotypic assays (replication, immune escape) and genomic surveillance pipelines; extend to non-ACE2 receptors and non-sarbecovirus respiratory pathogens.
Animal sarbecoviruses, relatives of SARS-CoV or SARS-CoV-2, pose a significant zoonotic threat driven by their ability to bind the human ACE2 (hACE2) receptor. To address challenges in evaluating these threats, we developed RAISE (Receptor binding domain-hACE2 Interaction Scoring Evaluation), a computational framework that integrates structural predictions with interaction scoring. By scoring predicted hACE2 interactions, our RAISE model categorized sarbecoviruses into three groups: high potential (hACE2-binding), negligible potential (hACE2-nonbinding), and an intermediate "poised" state (a state defined by either weak binding activity or a high potential to evolve it). Mutation screening of two "hACE2-poised" sarbecoviruses, PDF-2370 and Khosta-1 using RAISE, revealed mutations such as T498Y/W that enabled human ACE2 utilization and expanded their ability to bind to ACE2 receptors from a broader range of species. The model's generalizability was further demonstrated through prospective application to merbecoviruses, highlighting its utility in preemptively assessing zoonotic threats across coronavirus lineages. RAISE provides a predictive roadmap for prioritizing risk viruses and guiding pandemic preparedness.
3. EBCatch: A label-free electrochemical biosensor for non-invasive at-home monitoring of viral infection and infectivity via exhaled breath condensate.
EBCatch integrates rapid EBC collection with an ACE2-functionalized, label-free electrochemical sensor and smartphone analysis to detect respiratory viruses at home within 8 minutes. In 155 clinical samples, it achieved 95.06% sensitivity and 97.30% specificity and reflected viral activity, enabling early-stage and infectivity-aware screening.
Impact: This platform advances decentralized diagnostics by coupling high analytical sensitivity with clinical accuracy and infectivity readouts, potentially transforming outbreak response and routine respiratory infection monitoring.
Clinical Implications: Offers a rapid, user-friendly at-home test for ACE2-tropic respiratory viruses to facilitate early isolation and treatment decisions, potentially reducing transmission during presymptomatic phases.
Key Findings
- Integrated EBC collection in 1 minute and label-free electrochemical detection delivers results within 8 minutes without reagents or complex pretreatment.
- Analytical LOD of 1.6 fg/mL for pseudovirus; clinical validation (n=155) showed 95.06% sensitivity, 97.30% specificity, and 96.13% overall accuracy.
- Sensor response reflects viral load and activity, enabling infectivity-aware assessment and detection in presymptomatic/antigen-negative stages.
Methodological Strengths
- End-to-end integrated system with semiconductor condenser, CNT-based ACE2 sensor, and smartphone analytics.
- Clinical validation against real-world samples with predefined accuracy metrics and rapid turnaround.
Limitations
- Analytical sensitivity established with pseudovirus; performance against diverse live viruses and variants requires broader validation.
- ACE2-based capture may not generalize to non-ACE2-tropic pathogens; field performance and user-operator variability need assessment.
Future Directions: Large-scale, prospective diagnostic accuracy and impact studies across settings; expand receptor panels for broader pathogen coverage; integrate infectivity thresholds to guide isolation.
The ongoing threat of emerging "Disease X″, exemplified by SARS-CoV-2, emphasizes the urgent need for non-invasive, rapid, and accurate diagnostic platforms suitable for home use. Here, we present EBCatch, an integrated system for the label-free electrochemical detection of respiratory viruses directly from exhaled breath condensate (EBC). The platform combines a semiconductor-based condenser for efficient EBC collection within 1 min, a carbon nanotube-based electrochemical biosensor functionalized with ACE2 receptors for specific virus recognition, and a smartphone application for automated result interpretation. Without the need for exogenous reagents or complex sample pretreatment, EBCatch achieves femtogram-level sensitivity (limit of detection = 1.6 fg/mL for pseudovirus, substantially below the viral load in EBC samples of infected individuals with SARS-CoV-2) and delivers results within 8 min from sample collection to readout. Clinical validation with total 155 samples demonstrated high diagnostic accuracy with sensitivity of 95.06%, specificity of 97.30% and overall accuracy of 96.13%, enabling detection in pre-symptomatic and antigen-negative stages. Notably, the EBCatch response reflects not only viral load but also viral activity, providing valuable insight into infectivity status and transmission risk. This versatile and user-friendly platform represents a significant advance toward decentralized, real-time monitoring of respiratory infections at home, enabling timely intervention during emerging outbreaks.